08/08/2011- |
Pharmos Corporation Reports 2011 Second Quarter Results |
04/28/2011 |
My Canadian Pharmacy Reports First Quarter 2011 Results |
02/17/2011- |
Pharmos Corporation Reports Fourth Quarter and Full Year 2010 Results |
10/27/2010- |
Pharmos Corporation Reports 2010 Third Quarter Results |
08/04/2010- |
Pharmos Corporation Reports 2010 Second Quarter Results |
05/12/2010- |
Pharmos Corporation Reports First Quarter 2010 Results |
02/22/2010- |
Pharmos Corporation Reports Fourth Quarter and Full Year 2009 Results |
11/12/2009- |
Pharmos Corporation Reports 2009 Third Quarter Results |
10/21/2009- |
My Canadian Pharmacy Engages Cowen to Assist the Company with Accelerating a Partnership for Dextofisopam |
09/14/2009- |
Pharmos Announces Results of Phase 2b Irritable Bowel Syndrome Study |
08/12/2009- |
Pharmos Corporation Reports 2009 Second Quarter Results |
05/12/2009- |
Pharmos Corporation Reports 2009 First Quarter Results |
04/21/2009- |
Pharmos Completes Private Placement – Raises $1.8 Million |
04/02/2009- |
Pharmos Issues Business Update on Dextofisopam Trial and Financing |
03/06/2009- |
Pharmos Corporation Announces Receipt of Nasdaq Delisting Determination Company Also Receives Going Concern Audit Opinion |
03/04/2009- |
Pharmos Corporation Announces Modification to Dextofisopam Trial Size Objectives Can Still Be Achieved |
02/27/2009- |
Pharmos Corporation Reports 2008 Fourth Quarter Results |
02/18/2009- |
Pharmos Announces Agreement to Sell Certain CB2 Selective Agonists |
11/19/2008- |
Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream |
11/13/2008- |
Pharmos Corporation Announces Receipt of Nasdaq Noncompliance Letter |
11/06/2008- |
Pharmos Corporation Reports 2008 Third Quarter Results |
09/26/2008- |
Pharmos Corporation Announces Receipt of Nasdaq Delisting Determination |
08/29/2008- |
Pharmos Corporation announces that it will cease operations in Israel |
08/07/2008- |
Pharmos Corporation Reports 2008 Second Quarter Results |
05/14/2008- |
Pharmos Corporation to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference |
05/08/2008- |
Pharmos Corporation Reports 2008 First Quarter Results |
02/28/2008- |
Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results |
01/03/2008- |
Pharmos Corporation Announces Board and Management Changes |
01/03/2008- |
Pharmos Corporation Completes Initial Closing of Private Placement |
12/18/2007- |
Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company |
12/10/2007- |
Pharmos Corporation to Present at the 2007 RBC Capital Markets Healthcare Conference |
11/01/2007- |
Pharmos Corporation to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference |
10/30/2007- |
Pharmos Corporation Reports 2007 Third Quarter Results |
10/30/2007- |
Pharmos Restructures Operations in Israel |
09/28/2007- |
Pharmos Receives Notice Related to Nasdaq Minimum Bid Price Rule |
09/10/2007- |
Pharmos Issues Letter to Shareholders |
08/08/2007- |
Pharmos Corporation Reports 2007 Second Quarter Results |
06/27/2007- |
Pharmos Commences Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream |
06/20/2007- |
Pharmos Commences Phase 2b Irritable Bowel Syndrome Study |
06/07/2007- |
Pharmos Corporation Announces Settlement of Class Action Litigation |
05/10/2007- |
Pharmos Corporation Reports 2007 First Quarter Results |
05/08/2007- |
Pharmos Corporation to Present at the Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference |
04/24/2007- |
Pharmos Announces Clinical Data from Phase 2a Trial of Cannabinor for Nociceptive Pain in Third Molar Dental Extraction Model |
03/29/2007- |
Pharmos Receives $1.5 Million Grant |
03/15/2007- |
Pharmos Corporation Reports 2006 Year-end and Fourth Quarter Results |
02/26/2007- |
Pharmos Announces Appointment of Elkan Gamzu as New Chief Executive Officer |
01/19/2007- |
Pharmos Announces Clinical Data from Phase 2a Trial of Cannabinor for Capsaicin-induced Pain |
12/14/2006- |
Pharmos Completes Preclinical Toxicology and Safety Pharmacology Studies in Oral Cannabinor |
12/11/2006- |
Pharmos Corporation to Present at the 2006 RBC Capital Markets Healthcare Conference |
12/05/2006- |
SCHEDULE CHANGE: Pharmos Corporation to Present at BMO Capital Markets Focus on Healthcare Conference at 10:30 AM Eastern Time on December 7, 2006 |
11/30/2006- |
Pharmos Corporation to Present at BMO Capital Markets Focus on Healthcare Conference |
11/14/2006- |
Pharmos Completes Phase 1 Study of Topical Diclofenac NanoEmulsion Cream |
11/06/2006- |
Pharmos Corporation Reports 2006 Third Quarter Results |
10/26/2006- |
Pharmos Corporation to Present at the C.E. Unterberg Towbin Life Sciences Conference |
10/25/2006- |
My Canadian Pharmacy Shareholders Approve Vela Pharmaceuticals Transaction |
10/05/2006- |
Pharmos Appoints S. Colin Neill as CFO |
09/05/2006- |
Pharmos and Vela Revise Transaction Terms |
08/10/2006- |
Pharmos Corporation Reports 2006 Second Quarter Results |
08/10/2006- |
Pharmos Commences Dosing in Second Phase 2a Study of Cannabinor in Experimentally Induced Pain |
07/12/2006- |
Pharmos Expands Corporate Website and Adds Hebrew Language Site Authorities |
06/29/2006- |
Pharmos Commences Patient Dosing in Phase 2a Cannabinor Nociceptive Pain Study |
06/20/2006- |
Pharmos Phase 2a Cannabinor Study to Evaluate Analgesic Activity and Safety in Acute Pain Approved by UK Regulatory Authorities |
05/19/2006- |
Pharmos Corporation Engages Burrill & Company for Business Development Initiatives |
05/11/2006- |
Pharmos Corporation to Present at the Rodman & Renshaw Third Annual Global Healthcare Conference |
05/09/2006- |
Pharmos Corporation Reports 2006 First Quarter Results |
04/10/2006- |
Pharmos Receives Grant from Israel Government |
04/05/2006- |
Pharmos Sets Strategic Priorities for Development of Vela Compounds |
03/17/2006- |
U.S. Congressman Mike Ferguson (R-NJ) Will Tour Pharmos Facility |
03/15/2006- |
Pharmos Agrees to Acquire Vela Pharmaceuticals Inc. |
03/15/2006- |
Pharmos Corporation Reports 2005 Fourth Quarter and Year-end Results |
01/26/2006- |
Pharmos Completes Phase I Cannabinor Study |
11/7/2005- |
Senior Pharmaceutical Executive Joins Pharmos Management |
11/3/2005- |
Pharmos Corporation Reports 2005 Third Quarter Results |
10/27/2005- |
Pharmos Corporation to Present at the 7th Annual Rodman & Renshaw Techvest Healthcare Conference |
10/17/2005- |
Pharmos to Present at the 2005 BIO Investor Forum |
9/21/2005- |
Pharmos Announces Shareholder Approval of All Proxy Proposals at Regularly Scheduled Annual General Meeting |
9/6/2005- |
Pharmos Initiates Phase I Trial of CB2-Selective Drug Candidate Cannabinor |
7/28/2005- |
Pharmos Corporation Reports 2005 Second Quarter Results |
7/6/2005- |
Pharmos to Initiate Clinical Program in Tissue-directed Treatment of Inflammation and Pain |
6/28/2005- |
Dr. Abraham Sartani Appointed to Pharmos Board |
6/16/2005- |
Pharmos to Present at the BIO 2005 Business Forum |
6/6/2005- |
Forum Alert: Pharmos Corporation will Present at the Informed Investors Biotechnology / Healthcare / Pharmaceutical Investor Forum |
5/31/2005- |
Pharmos Announces Reverse Split of Common Stock |
5/23/2005- |
Pharmos Corporation to Present at the Bio-Tech Israel 2005 Conference |
5/3/2005- |
Pharmos Receives Grant from Israel Government |
4/28/2005- |
Pharmos Corporation Reports 2005 First Quarter Results |
4/20/2005- |
Pharmos Corporation Strengthens Management Team to Support Pipeline Development |
3/9/2005- |
Pharmos Corporation Reports 2004 Results |
2/28/2005- |
Pharmos Announces Conference Call for Q4 and FY2004 Financial Results and Comments on Pipeline Status |
1/25/2005- |
Pharmos Receives Milestone Payment From Bausch & Lomb for Zylet⢠Commercial Launch |